Plus Therapeutics PSTV shares are trading higher on Monday.
The company announced it has entered into an agreement to license multiple rare cancer drug product candidates from NanoTx for an upfront payment of $400,000 in cash and $300,000 in stock.
Plus Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
The company's shares were trading up 63.19% to $2.35 at time of publication. The stock has a 52-week high of $22.89 and a 52-week low of 93 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
